echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > What is troglitazone?

    What is troglitazone?

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Troglitazone is a kind of thiazolidinedione (TZD) Its main use is anti diabetes and anti-inflammatory drugs It plays a role in peroxisome proliferator activated receptors (PPARs) The drug came into the market in the late 1990s As an oral tablet, it was prescribed by doctors It usually starts from 200 mg per day, is taken at meals, and increases by 100-200 mg as needed Although once thought to promote the function of liver, muscle and adipose tissue, the market exists for a short time By the spring of 2000, pharmaceutical companies had voluntarily stopped the production of the drug Troglitazone was developed by "Daiichi Sankyo" company in Japan After being approved by the food and Drug Administration of the United States in January 1997, the drug entered the mainstream manufacturing industry of the United States through "Park e-davis" Prior to approval, FDA official "John gueriguia" examined troglitazone, which had been strongly opposed because of its hepatotoxicity Thiazolidinediones (also known as azones) are mainly used to treat type 2 diabetes PPARs attract ligands from free fatty acids and arachidonic acids (signaling molecules formed by oxidation of 20 carbon essential fatty acids) The body system that manipulates inflammation and immunity, as well as part of the central nervous system, is controlled by 20 carbon essential fatty acids (EFAs) It can be found in omega-3 and omega-6 fatty acids Changing the level of EFAs in vivo can affect their control function PPARs are a group of nuclear receptor proteins, which are transfer factors regulating gene expression Cell differentiation and development, as well as metabolism, are affected by PPARs However, when troglitazone and other TZD drugs are targeted at PPARs, they not only increase the hepatotoxicity, but also inhibit the immune system, leading to the specific response of drug-induced hepatitis In December 1997, after learning that the drug had side effects on the liver, the British government banned the sale of troglitazone on the market The United States withdrew the drug from the market in 2000, followed by the Philippines, Australia and Japan Although troglitazone can reduce inflammation, more and more harmful effects have been found On March 21, 2000, Parke Davis voluntarily stopped the production of the drug.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.